 |
One of the largest API manufacturers in Asia, Aurobindo Pharma has commercialised over hundred APIs. Aurobindo's products are spread over six major areas encompassing Antibiotics, Anti-Retro Virals, CVS, CNS, Gastroenterologicals, and Anti-Allergics. |
 |
Aurobindo’s R & D strengths lie in developing intellectual property in non-infringing processes and resolving complex chemistry challenges. In the process, Aurobindo develops new drug delivery systems, dosage formulations and applies new technology for better processes. |
 |
|
 |
 |
 |
 |
Important Mile Stones
 |
Merger of APL Life Sciences Ltd & Senor Organics Pvt. Ltd. |
 |
Issue of USD 200 Million FCCBs |
 |
Achieved Turnover of Rs.23 billion |
 |
Establishment of a WOS for Research activities |
| more >> |
|
|
 |
|
|
|
 |
 |
|
|
 |
 |
 |
 |
Stock Prices - April 2008 |
 |
 |
| STOCK EXCHANGE |
OPEN |
HIGH |
LOW |
CLOSE |
VOLUME TRADED |
| BSE |
300.00 |
347.00 |
284.00 |
328.90 |
1,185,043 |
| NSE |
295.50 |
347.20 |
283.20 |
329.65 |
3,075,454 |
|
 |
|
|
 |
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
| One of the largest API manufacturers in Asia, Aurobindo Pharma has commercialised over hundred APIs. |
 |
|
 |
|
|
 |
 |
 |
 |
| Aurobindo's R & D strengths lie in developing intellectual property in non-infringing processes and resolving complex chemistry challenges. |
|
 |
|
|
 |
 |
| |
 |
 |
|
|
  |
 |
|
|
 |
|
|